A novel synergistic galactomannan-based unit dosage form for sustained release of acarbose

AAPS PharmSciTech

Volumn 13, Issue 1, 2012, Pages 262-275

  Kumar, Ruchita V ^a   Sinha, Vivek Ranjan ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Acarbose; Antidiabetic; Boswellia gum; Fenugreek gum; Galactomannans; Locust bean gum; Sustained release

Indexed keywords

ACARBOSE; ALGAROBA; GALACTOMANNAN; GLUCOSE; MAGNESIUM STEARATE; TALC; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BOSWELLIA; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DECREASED APPETITE; DIABETES MELLITUS; DIARRHEA; DRUG DOSAGE FORM; DRUG PURIFICATION; DRUG STABILITY; DRUG STRUCTURE; EPIGASTRIC FULLNESS; FENUGREEK; FLATULENCE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MATRIX TABLET; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; TABLET FRIABILITY; TABLET HARDNESS; TABLET THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ACARBOSE; ANIMALS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOSAGE FORMS; DRUG SYNERGISM; GALACTANS; GASTROINTESTINAL TRACT; MALE; MANNANS; PLANT GUMS; RANDOM ALLOCATION; RATS; RESINS, PLANT;

EID: 84861101158     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9724-9     Document Type: Article

References (59)

1. Fan J, Wang K, Liu M, He Z. In vitro evaluations of konjac glucomannan and xanthan gum mixture as the sustained release material of matrix tablet. Carbohydr Polym. 2008;73(2):241-7.
2. Sinha VR, Kumria R. Coating polymers for colon specific drug delivery: a comparative in vitro evaluation. Acta Pharmaceutica. 2003;53(1):41-7. (Pubitemid 36514234)
3. Sinha VR, Al-Azaki AA, Kumar RV. Novel Lannea Woodier gum matrices for controlled release of drugs. Carbohydr Polym. 2011;83(4):1492-8.
4. Bruneton J. Heterogenous polysaccharides. Pharmacognosy phytochemistry medicinal plants. 2nd ed. France: Lavoisier; 1999. p. 99-105.
5. Ribes G, Sauvaire Y, Da Costa C, Baccou JC, Loubatieres-Mariani MM. Antidiabetic effects of subfractions from fenugreek seeds in diabetic dogs. Proc Soc Exp Biol Med. 1986;182:159-66. (Pubitemid 16087243)
6. Mishkinsky J, Joseph B, Sulman FG. Hypoglycaemic effect of trigonelline. Lancet. 1967;2(7529):1311.
7. Bever BO, Zahnd GR. Plants with oral hypoglycaemic action. Q J Crude Drug Res. 1979;17(3-4):139-96.
8. Hannan JMA, Ali L, Rokeya B, Khaleque J, Akhter M, Flatt PR, et al. Soluble dietary fibre fraction of Trigonella foenumgraecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. Br J Nutr. 2007;97(03):514-21. (Pubitemid 46662041)
9. Mowla A, Alauddin M, Rahman MA, Ahmed K. Antihyperglycemic effect of Trigonella foenum-graecum(fenugreek) seed extract in alloxan-induced diabetic rats and its use in diabetes mellitus: a brief qualitative phytochemical and acute toxicity test on the extract. African J Tradit, Complement Altern Med. 2009;6(3):255-61.
10. Madar Z, Abel R, Samish S, Arad J. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. Eur J Clin Nutr. 1988;42(1):51.
11. Sharma RD, Raghuram TC, Rao VD. Hypolipidaemic effect of fenugreek seeds. A clinical study. Phytother Res. 1991;5 (3):145-7.
12. Al-Habori M, Raman A. Antidiabetic and hypocholesterolaemic effects of fenugreek. Phytother Res. 1998;12(4):233-42. (Pubitemid 28331456)
13. Tsai AC, Peng B. Effects of locust bean gum on glucose tolerance, sugar digestion, and gastric motility in rats. J Nutr. 1981;111(12):2152.
14. Edwards CA, Blackburn NA, Craigen L, Davison P, Tomlin J, Sugden K, et al. Viscosity of food gums determined in vitro related to their hypoglycemic actions. Am J Clin Nutr. 1987;46(1):72.
15. Feldman N, Norenberg C, Voet H, Manor E, Berner Y, Madar Z. Enrichment of an Israeli ethnic food with fibres and their effects on the glycaemic and insulinaemic responses in subjects with non-insulin-dependent diabetes mellitus. Br J Nutr. 1995;74 (05):681-8.
16. Venkatarajua MP, Gowdaa DV, Rajeshb KS, Shivakumara HG. Xanthan and locust bean gum (from Ceratonia siliqua) matrix tablets for oral controlled delivery of propranolol hydrochloride. Asian J Pharm Sci. 2007;2:239-48.
17. Maiti S, Dey P, Banik A, Sa B, Ray S, Kaity S. Tailoring of locust bean gum and development of hydrogel beads for controlled oral delivery of glipizide. Drug Deliv. 2010;17(5):288-300.
18. Zutsi U, Rao PG, Kaur S. Mechanism of cholesterol lowering effect of Salai guggal ex-Boswellia serrata Roxb. Indian J Pharmacol. 1986;18:182-3.
19. Kavitha JV, Rosario JF, Chandran J, Anbu P. Hypoglycemic and other related effects of Boswellia glabra in alloxan-induced diabetic rats. Indian J Physiol Pharmacol. 2007;51(1):29.
20. Ilango K, Valentina P, Umarani N, Chitra V. Antihyperglycemic activity of methanolic extract of oleogum resin of Boswellia serrata Roxb. Int J Chem Sci. 2009;7(1):343-8.
21. Clissold SP, Acarbose EC. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1988;35(3):214.
22. Krause HP, Keup U, Thomas G, Puls W. Reduction of carbohydrate-induced hypertriglyceridemia in (fa, fa) 'Zucker' rats by the a-glucosidase inhibitor acarbose (BAY g 5421). Metabolism. 1982;31:710-4. (Pubitemid 12070696)
23. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet. 2002;359(9323):2072-7. (Pubitemid 34680970)
24. Hillebrand I, Boehme K, Graefe KH, Wehling K. The effect of new α-glucosidase inhibitors (Baym1099 and Bayo1248) on meal-stimulated increases in glucose and insulin levels in man. KIinische Wochenschrifi. 1986;64:393-6. (Pubitemid 16102914)
25. Morrison JU. Method and composition for controlled release acarbose formulations (US6849609). Assigned to Morrison. 2001.
26. Goldman D, Amatruda J, Pörtner C, Brendel E, Bosche P (inventors). Sustained release formulations comprising α-glucosidase inhibitors. 1999.
27. Sriamornsak P, Thirawong N, Weerapol Y, Nunthanid J, Sungthongjeen S. Swelling and erosion of pectin matrix tablets and their impact on drug release behavior. Eur J Pharm Biopharm. 2007;67(1):211-9. (Pubitemid 46991322)
28. Tsong Y, Sathe PM, Shah VP. In vitro dissolution profile comparison. In: Chow SC, editor. Encyclopedia of biopharmaceutical statistics. New York: Marcel Dekker; 2003. p. 456-62.
29. Higuchi T. Rate of release of medications from ointment bases containing drugs in suspension. J Pharm Sci. 1961;50:874-5.
30. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of potassium chloride release from compressed, hydrophilic, polymeric matrices: Effect of entrapped air. J Pharm Sci. 1983;72(10):1189-91. (Pubitemid 13013640)
31. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23(8):923-31.
32. Maurya SK, Raj K, Srivastava AK. Antidyslipidaemic activity of Glycyrrhiza glabra in high fructose diet induced dsyslipidaemic Syrian golden hamsters. Indian J Clin Biochem. 2009;24(4):404-9.
33. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969;6(1):24-7.
34. Hedge SS, Moy TM, Perry MR, Loeb M, Eglen RM. Evidence for the involvement of 5-hydroxytryptamine 4 receptors in 5-hydroxytryptophan-induced diarrhea in mice. J Pharm Exp Ther. 1994;271(2):741.
35. Girard P, Pansart Y, Gillardin JM. Inducible nitric oxide synthase involvement in the mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhoea in rats. Nitric Oxide. 2005;13(3):163-9. (Pubitemid 41443560)
36. Frommer W, Junge B, Keup U, Muller L, Puls W, Schmidt D. Amino sugar derivatives (US4062950). Bayer Aktiengesellschaft (DT). 1977.
37. Brummer Y, Cui W, Wang Q. Extraction, purification and physicochemical characterization of fenugreek gum. Food Hydrocoll. 2003;17(3):229-36.
38. Doyle JP, Lyons G, Morris ER. New proposals on " hyperentanglement" of galactomannans: solution viscosity of fenugreek gum under neutral and alkaline conditions. Food Hydrocoll. 2009;23(6):1501-10.
39. Gaisford SE, Harding SE, Mitchell JR, Bradley TD. A comparison between the hot and cold water soluble fractions of two locust bean gum samples. Carbohydr Polym. 1986;6(6):423-42.
40. Hui PA, Neukom H. Some properties of galactomannans. Tappi. 1964;47(1):39-42.
41. Dakia PA, Blecker C, Robert C, Wathelet B, Paquot M. Composition and physicochemical properties of locust bean gum extracted from whole seeds by acid or water dehulling pre-treatment. Food Hydrocoll. 2008;22(5):807-18. (Pubitemid 351282428)
42. Melia CD. Hydrophilic matrix sustained release systems based on polysaccharide carriers. Crit Rev Therap Drug Carrier Sys. 1991;8(4):395.
43. Hardy IJ, Windberg-Baarup A, Neri C, Byway PV, Booth SW, Fitzpatrick S. Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using polyvinyl pyrrolidone. Int J Pharm. 2007;337(1-2):246-53. (Pubitemid 46756059)
44. Mulye NV, Turco SJ. Matrix type tablet formulation for controlled release of highly water soluble drugs. Drug Dev Ind Pharm. 1994;20(17):2633-43. (Pubitemid 24288825)
45. Merchant HA, Shoaib HM, Tazeen J, Yousuf RI. Once-daily tablet formulation and in vitro release evaluation of Cefpodoxime using hydroxypropyl methylcellulose: a technical note. AAPS PharmSciTech. 2006;7(3):178-83.
46. Sujja-areevath J, Munday DL, Cox PJ, Khan KA. Release characteristics of diclofenac sodium from encapsulated natural gum mini-matrix formulations. Int J Pharm. 1996;139:53-62. (Pubitemid 26276267)
47. Datta R, Bandyopadhyay AK. Development of a new nasal drug delivery system of diazepam with natural mucoadhesive agent from Trigonella foenum-graecum L. J Sci Ind Res. 2005;64:973-7. (Pubitemid 41825412)
48. Tuleu C, Andrieux C, Boy P, Chaumeil JC. Gastrointestinal transit of pellets in rats: effect of size and density. Int J Pharm. 1999;180(1):123-31. (Pubitemid 29131450)
49. Omidian H, Park K. Oral targeted drug delivery systems: gastric retention devices. 2010. doi:10.1002/9780470640487.ch12.
50. de Moura RF, Ribeiro C, de Oliveira JA, Stevanato E, de Mello MAR. Metabolic syndrome signs in Wistar rats submitted to different high-fructose ingestion protocols. Br J Nutr. 2009;101 (08):1178-84.
51. Scheen AJ. Clinical efficacy of acarbose in diabetesmellitus: a critical review of controlled trials. Diabetes Metabol. 1998;24(4):311.
52. Carswell N, Michaelis OE, Prather ES. Effect of acarbose (Bay 5421) on expression of non-insulin dependent diabetes-mellitus in sucrose-fed SHR/N-corpulent rats. J Nutr. 1989;119:388-94. (Pubitemid 19097096)
53. Matsumura M, Monden T, Miyashita Y, Kawagoe Y, Shimizu H, Nakatani Y, et al. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009;26(6):660-6.
54. Mughal MA, Memon MY, Zardari MK, Tanwani RK, Ali M. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes. J Pak Med Assoc. 2000;50(5):152.
55. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab. 2006;91(3):837.
56. Vedula U, Schnitzer-Polokoff R, Tulp OL. The effect of acarbose on the food intake, weight gain, and adiposity of LA/N-cp rats. Comp Biochem Physiol Part A: Physiol. 1991;100(2):477-82.
57. Balfour JA, McTavish D. Acarbose.An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 1993;46(6):1025.
58. Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care. 1998;21(3):416.
59. Hauner H, Petzinna D, Sommerauer B, Toplak H. Effect of acarbose on weight maintenance after dietary weight loss in obese subjects. Diabetes Obes Metab. 2001;3(6):423-7. (Pubitemid 34030861)